Glaukos (GKOS) Stock Could Still Look Reasonable Despite Its 348% Run

Glaukos has been on a striking run, and with the stock around US$233 at the last close after years of strong gains, the live question is whether that price is aligned with what its cash flows can support. Recent news around record sales, index changes and a sharp move higher has shifted expectations, so the focus now turns to what the company’s underlying cash generation really justifies.

• Glaukos has delivered a very large 5 year return of 347.6%, which puts a lot of future cash flow already on the line for anyone looking at the valuation today.
• Fresh earnings news around stronger sales, a move into profit and higher revenue expectations can reshape how reliably and how quickly the business converts its glaucoma and corneal therapies into cash.
• If you'd rather focus on sales, this one's for you. See why Glaukos's 20.0x P/S tells a different valuation story.

The stock's next move may depend on whether the current share price is reasonable once you weigh it against the cash flows implied by the Discounted Cash Flow (DCF) intrinsic value estimate.

If you want a clearer view of how Glaukos fits into the wider opportunity set, compare it with other companies in the 35 high quality undervalued stocks for a cash flow focused perspective.

Does Glaukos Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here projects what Glaukos might generate for shareholders based on future free cash flows rather than near term earnings swings. Latest twelve month free cash flow sits at about $35.5 million, while the model assumes those cash flows keep growing, with forecasts climbing into the hundreds of millions of dollars over the next decade.

At a share price of $233.04, the stock is being compared with DCF projections that put its estimated intrinsic value substantially above the current share price, so the implied return rests heavily on those growth expectations actually showing up in cash. The record third quarter of 2026, with $211.0 million of net sales and a move into profit, feeds into that story because it gives the cash generation path in the DCF a more concrete backing than pure blue sky forecasts. Find out what Glaukos could be worth using our Discounted Cash Flow (DCF) estimate.

The Glaukos Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Glaukos act as the missing link between the valuation puzzle above and the specific future that price implies. These scenarios spell out in plain terms which paths for Glaukos' growth, margins and earnings would need to play out for the stock to be worth materially more or less than today. Where a single valuation ratio or DCF outputs one figure, Narratives unpack the future behind that number so you can monitor whether reality is matching the story.

Glaukos brings out sharply different views, with one camp treating the recent run as only part of the upside and another arguing the story is already well reflected.

Bull case: 14% undervalued

"The new exclusive license for a tri specific retinal biologic and the associated platform introduces a separate retinal biologics franchise…"

Discover why this Narrative puts Glaukos at 14% undervalued.

Bear case: 17% overvalued

"The company remains exposed to reimbursement pressure because five of seven Medicare Administrative Contractors have proposed local coverage determinations for iDose TR…"

Explore why this Narrative puts Glaukos at 17% overvalued.

Glaukos valuation leaves one crucial piece of the puzzle unresolved

Glaukos can only go where the people in charge decide to steer it, and how those leaders are rewarded can shape every capital allocation call you care about. See who runs Glaukos and how they are paid.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com